Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

GENFIT Shares Surge 84% in One Quarter, Approaching a Key Resistance Level

GENFIT saw an increase of 3.53% this Thursday morning, reaching 8.94 euros, bringing its quarterly performance to over 84%. The stock of the biopharmaceutical company specializing in liver and metabolic diseases is now very close to a critical technical threshold, just weeks before the release of its annual 2025 results.


GENFIT Shares Surge 84% in One Quarter, Approaching a Key Resistance Level

Current Trading Status

GENFIT's stock is priced at 8.94 euros at the start of the session, up 3.53% compared to the previous day's close of 8.64 euros. This level places the stock a very short distance from the identified resistance at 9.09 euros, a threshold whose crossing could pave the way for a new phase of appreciation. Technically, the price is significantly above its 50-day and 200-day moving averages, set respectively at 6.36 euros and 4.36 euros, indicating a solidly established upward trend over several months. However, the RSI is at 70, a level that indicates the stock is entering an overbought zone, a territory where profit-taking becomes statistically more frequent. This configuration calls for caution as the valuation has more than doubled in a year (+168%).

Upcoming Financial Calendar

The schedule for the coming weeks could be a crucial catalyst for the stock's trajectory. GENFIT is set to publish its annual 2025 results on April 2nd, followed by the first quarter 2026 revenue expected on May 21st. The general meeting is scheduled for June 15th. These close financial events should fuel discussions on the stock, especially as monthly volatility remains high at 17.53%. It should be noted that the stock's beta is very low at 0.14, indicating a limited correlation with general market fluctuations. GENFIT's performance is therefore primarily dependent on factors specific to the company—clinical advancements, strategic partnerships, or financial results—rather than market trends. The slight weekly decline of 1.54% does not challenge the dynamics observed over the past quarter but illustrates the stock's ability to experience consolidation movements within a pronounced upward trajectory.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 36,4 millions d'euros
  • Quarterly revenue: 36,4 millions d'euros
  • Revenue growth: -7,1 %
Guidance from the release
  • « conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
  • Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
  • Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
  • Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
  • Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
  • Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
  • Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours